High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer

Carlo Barone, Antonio Astone, Carlo Garufi, Antonio Grieco, Antonio Cavallaro, Gaetano Netri, Simonetta Rossi, Alessandra Cassano, Enrico Ricevuto, Maria R. Noviello, Gino Gambassi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The therapeutic activity of 5-FU in large bowel cancer is enhanced by increasing the intracellular pool of reduced folates. We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days. None had been given previous radio- or chemotherapy. All had measurable disease. Not one complete response was observed. Thirteen of the 39 evaluable patients showed partial response. Median duration of response was 9+ months. The probability of 50% survival was 15 months for all evaluable patients. There was no case of severe toxicity and the principal toxic effects were oral mucositis and diarrhea. To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer.

Original languageEnglish
Pages (from-to)1303-1306
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number9
DOIs
Publication statusPublished - 1987

Fingerprint

Leucovorin
Fluorouracil
Colonic Neoplasms
Drug Therapy
Stomatitis
Poisons
Folic Acid
Diarrhea
Radiotherapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. / Barone, Carlo; Astone, Antonio; Garufi, Carlo; Grieco, Antonio; Cavallaro, Antonio; Netri, Gaetano; Rossi, Simonetta; Cassano, Alessandra; Ricevuto, Enrico; Noviello, Maria R.; Gambassi, Gino.

In: European Journal of Cancer and Clinical Oncology, Vol. 23, No. 9, 1987, p. 1303-1306.

Research output: Contribution to journalArticle

Barone, C, Astone, A, Garufi, C, Grieco, A, Cavallaro, A, Netri, G, Rossi, S, Cassano, A, Ricevuto, E, Noviello, MR & Gambassi, G 1987, 'High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer', European Journal of Cancer and Clinical Oncology, vol. 23, no. 9, pp. 1303-1306. https://doi.org/10.1016/0277-5379(87)90112-X
Barone, Carlo ; Astone, Antonio ; Garufi, Carlo ; Grieco, Antonio ; Cavallaro, Antonio ; Netri, Gaetano ; Rossi, Simonetta ; Cassano, Alessandra ; Ricevuto, Enrico ; Noviello, Maria R. ; Gambassi, Gino. / High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. In: European Journal of Cancer and Clinical Oncology. 1987 ; Vol. 23, No. 9. pp. 1303-1306.
@article{ee9cbd52af04417a916e2c7861d451a1,
title = "High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer",
abstract = "The therapeutic activity of 5-FU in large bowel cancer is enhanced by increasing the intracellular pool of reduced folates. We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days. None had been given previous radio- or chemotherapy. All had measurable disease. Not one complete response was observed. Thirteen of the 39 evaluable patients showed partial response. Median duration of response was 9+ months. The probability of 50{\%} survival was 15 months for all evaluable patients. There was no case of severe toxicity and the principal toxic effects were oral mucositis and diarrhea. To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer.",
author = "Carlo Barone and Antonio Astone and Carlo Garufi and Antonio Grieco and Antonio Cavallaro and Gaetano Netri and Simonetta Rossi and Alessandra Cassano and Enrico Ricevuto and Noviello, {Maria R.} and Gino Gambassi",
year = "1987",
doi = "10.1016/0277-5379(87)90112-X",
language = "English",
volume = "23",
pages = "1303--1306",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "9",

}

TY - JOUR

T1 - High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer

AU - Barone, Carlo

AU - Astone, Antonio

AU - Garufi, Carlo

AU - Grieco, Antonio

AU - Cavallaro, Antonio

AU - Netri, Gaetano

AU - Rossi, Simonetta

AU - Cassano, Alessandra

AU - Ricevuto, Enrico

AU - Noviello, Maria R.

AU - Gambassi, Gino

PY - 1987

Y1 - 1987

N2 - The therapeutic activity of 5-FU in large bowel cancer is enhanced by increasing the intracellular pool of reduced folates. We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days. None had been given previous radio- or chemotherapy. All had measurable disease. Not one complete response was observed. Thirteen of the 39 evaluable patients showed partial response. Median duration of response was 9+ months. The probability of 50% survival was 15 months for all evaluable patients. There was no case of severe toxicity and the principal toxic effects were oral mucositis and diarrhea. To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer.

AB - The therapeutic activity of 5-FU in large bowel cancer is enhanced by increasing the intracellular pool of reduced folates. We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days. None had been given previous radio- or chemotherapy. All had measurable disease. Not one complete response was observed. Thirteen of the 39 evaluable patients showed partial response. Median duration of response was 9+ months. The probability of 50% survival was 15 months for all evaluable patients. There was no case of severe toxicity and the principal toxic effects were oral mucositis and diarrhea. To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023510053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023510053&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(87)90112-X

DO - 10.1016/0277-5379(87)90112-X

M3 - Article

C2 - 3500048

AN - SCOPUS:0023510053

VL - 23

SP - 1303

EP - 1306

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -